Synthesis and Early ADME Evaluation of a Novel Scaffold, Tetrahydro-6H-pyrido[3,2-b]azepin-6-one

Koen Muylaert; Martyna Jatczak; Benjamin Wuyts; Laurens M. De Coen; Kristof Van Hecke; Hans Loones; Janneke Keemink; Daniel García; Sven Mangelinckx; Pieter Annaert; Christian V. Stevens

doi:10.1055/s-0033-1341258

Synlett, Table of Contents

Synlett 2014; 25(10): 1443-1447
DOI: 10.1055/s-0033-1341258

letter

Synthesis and Early ADME Evaluation of a Novel Scaffold, Tetrahydro-6H-pyrido[3,2-b]azepin-6-one

Authors

Koen Muylaert

^aDepartment of Sustainable Organic Chemistry and Technology, Faculty of Bioscience Engineering, Ghent University, Coupure Links 653, 9000 Ghent, Belgium Fax: +32(9)2646221 Email: Chris.Stevens@UGent.be
Martyna Jatczak

^aDepartment of Sustainable Organic Chemistry and Technology, Faculty of Bioscience Engineering, Ghent University, Coupure Links 653, 9000 Ghent, Belgium Fax: +32(9)2646221 Email: Chris.Stevens@UGent.be
Benjamin Wuyts

^bDrug Delivery and Disposition, KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, O&N II, Herestraat 49 – Box 921, 3000 Leuven, Belgium
Laurens M. De Coen

^aDepartment of Sustainable Organic Chemistry and Technology, Faculty of Bioscience Engineering, Ghent University, Coupure Links 653, 9000 Ghent, Belgium Fax: +32(9)2646221 Email: Chris.Stevens@UGent.be
Kristof Van Hecke

^cXStruct, Department of Inorganic and Physical Chemistry, Faculty of Sciences, Ghent University, Krijgslaan 281, S3, 9000 Gent, Belgium
Hans Loones

^aDepartment of Sustainable Organic Chemistry and Technology, Faculty of Bioscience Engineering, Ghent University, Coupure Links 653, 9000 Ghent, Belgium Fax: +32(9)2646221 Email: Chris.Stevens@UGent.be
Janneke Keemink

^bDrug Delivery and Disposition, KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, O&N II, Herestraat 49 – Box 921, 3000 Leuven, Belgium
Daniel García

^aDepartment of Sustainable Organic Chemistry and Technology, Faculty of Bioscience Engineering, Ghent University, Coupure Links 653, 9000 Ghent, Belgium Fax: +32(9)2646221 Email: Chris.Stevens@UGent.be
Sven Mangelinckx

^aDepartment of Sustainable Organic Chemistry and Technology, Faculty of Bioscience Engineering, Ghent University, Coupure Links 653, 9000 Ghent, Belgium Fax: +32(9)2646221 Email: Chris.Stevens@UGent.be
Pieter Annaert

^bDrug Delivery and Disposition, KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, O&N II, Herestraat 49 – Box 921, 3000 Leuven, Belgium
Christian V. Stevens*

^aDepartment of Sustainable Organic Chemistry and Technology, Faculty of Bioscience Engineering, Ghent University, Coupure Links 653, 9000 Ghent, Belgium Fax: +32(9)2646221 Email: Chris.Stevens@UGent.be

Abstract

All articles of this category

Abstract

The synthesis and preliminary ADME evaluation of novel 4-(trifluoromethyl)-5,7,8,9-tetrahydro-6H-pyrido[3,2-b]azepin-6-ones is presented. The key step is a ring expansion of 4-(trifluoromethyl)-7,8-dihydroquinolin-5(6H)-ones via a Beckmann rearrangement. The rearrangement opens up possibilities to access novel unexplored scaffolds for medicinal chemistry. The biopharmaceutical profiling revealed a strong structural dependency of the druglike properties.

Key words

bioorganic chemistry - fluorine - fused-ring systems - pyridines - ring expansion

Full Text

References

References and Notes
1 Evans BE, Rittle KE, Bock MG, DiPardo RM, Freidinger RM, Whitter WL, Lundell GF, Veber DF, Anderson PS. J. Med. Chem. 1988; 31: 2235
2 Nicolaou KC, Pfefferkorn JA, Roecker AJ, Cao G.-Q, Barluenga S, Mitchell HJ. J. Am. Chem. Soc. 2000; 122: 9939
3 Horton DA, Bourne GT, Smythe ML. Chem. Rev. 2003; 103: 893
4 Mason JS, Morize I, Menard PR, Cheney DL, Hulme C, Labaudiniere RF. J. Med. Chem. 1999; 42: 3251
5 Costantino L, Barlocco D. Curr. Med. Chem. 2006; 13: 65
6 Barrios V, Escobar C. Expert Rev. Cardiovasc. Ther. 2010; 8: 1653
7 Lüscher B, Keller CA. Pharmacol. Ther. 2004; 102: 195
8 Bioorganic and Medicinal Chemistry of Fluorine . Begue J.-P, Bonnet-Delpon D. John Wiley and Sons; Hoboken, NJ: 2008
9 Purser S, Moore PR, Swallow S, Gouverneur V. Chem. Soc. Rev. 2008; 37: 320
10 Hoyt SB, London C, Park M. Tetrahedron Lett. 2009; 50: 1911
11 Hussenether T, Huebner H, Gmeiner P, Troschütz R. Bioorg. Med. Chem. 2004; 12: 2625
12 Setoi H, Ohkawa T, Zenkoh T, Hemmi K, Tanaka H. EP 620216A1, 1994
13 Fisher MH, Wyvratt MJ, Schoen WR, Devita RJ. WO 9216524A1, 1992
14 Paglietti G, Loriga M. J. Chem. Res., Synop. 1986; 284
15 Bauer A, Weber KH, Unruh M. Arch. Pharm. (Weinheim, Ger.) 1972; 305: 557
16 Liu J, Guideen D. WO 2012015693A1, 2012
17 Marfat A, Robinson RP. US 5811432A, 1998
18 Robinson RP, Donahue KM, Son PS, Wagy SD. J. Heterocycl. Chem. 1996; 33: 287
19 Robinson RP, Marfat A. EP 436333A2, 1991
20 Kiyoto T, Ando J, Tanaka T, Tsutsui Y, Yokotani M, Noguchi H, Ushiyama F, Urabe H, Horikiri H. JP 2009149618A, 2009
21 Kiyoto T, Ando J, Tanaka T, Tsutsui Y, Yokotani M, Noguchi T, Ushiyama F, Urabe H, Horikiri H. WO 2007138974A1, 2007
22 Tsoung J, Panteleev J, Tesch M, Lautens M. Org. Lett. 2014; 16: 110
23 Matsufuji T, Shimada K, Kobayashi S, Kawamura A, Fujimoto T, Arita T, Hara T, Konishi M, Abe-Ohya R, Izumi M, Sogawa Y, Nagai Y, Yoshida K, Takahashi H. Bioorg. Med. Chem. Lett. 2014; 24: 750
24 Bracke ME, Vanhoecke BW. A, Derycke L, Bolca S, Possemiers S, Heyerick A, Stevens CV, De Keukeleire D, Depypere HT, Verstraete W, Williams CA, McKenna ST, Tomar S, Sharma D, Prasad AK, DePass AL, Parmar VS. Anti-Cancer Agents Med. Chem. 2008; 8: 171
25 Rammeloo T, Stevens CV, De Kimpe N. J. Org. Chem. 2002; 67: 6509
26 Rammeloo T, Stevens CV. Chem. Commun. 2002; 250
27 Wauters I, De Blieck A, Muylaert K, Heugebaert TS. A, Stevens CV. Eur. J. Org. Chem. 2014; 1296
28 Heugebaert T, Van Hevele J, Couck W, Bruggeman V, Van der Jeught S, Masschelein K, Stevens CV. Eur. J. Org. Chem. 2010; 1017
29 Herbert B, Schumacher R, Dai G, Xie W. WO 2009055437A2, 2009
30 Cyclohexane-1,3-dione (22.42 g, 200 mmol, 1 equiv) was dissolved in anhydrous toluene (250 mL) and NH₄OAc (14.42 g, 200 mmol, 1 equiv) was added and refluxed under Dean–Stark conditions for 4 h.Compound 2: ¹H NMR (300 MHz, CDCl₃): δ = 1.99 (2H, tt, J = 6.1 Hz, J = 6.1Hz, CH₂CH ₂CH₂), 2.30 (2 H, t, J = 6.1 Hz, CH ₂C_qNH₂), 2.35 (2 H, t, J = 6.1Hz, CH ₂CO), 4.59 (2 H, br. s, NH ₂), 5.26 (1 H, CH). ¹³C NMR (75 MHz, CDCl₃): δ = 21.8, 28.8, 35.9, 99.9, 167.2, 198.0.
31 Volochnyuk DM, Pushechnikov AO, Krotko DG, Sibgatulin DA, Kovalyova SA, Tolmachev AA. Synthesis 2003; 1531
32 3-Aminocyclohex-2-en-1-one (5 g, 1 equiv) was dissolved in AcOH (200 mL) and an appropriate 1-substituted 4,4,4-trifluoro-1,3-dione (1.5 equiv) was added and refluxed for 7 h.Compound 4a: ¹H NMR (300 MHz, CDCl₃): δ = 2.20 (2 H, tt, J = 6.1, 6.1 Hz, CH₂CH ₂CH₂), 2.67 (3 H, s, CH₃), 2.75 (2 H, t, J = 6.1Hz, CH ₂CO), 3.20 (2 H, t, J = 6.1Hz, CH ₂C_qN), 7.45 (1 H, s, CH). ¹³C NMR (75 MHz, CDCl₃): δ = 21.3, 25.1, 33.6, 39.8, 120.0, 122.5, 123.2, 137.3, 163.7, 165.4, 195.6. ¹⁹F NMR (282 MHz, CDCl₃): δ = –61.7.
33 Pyrko AN. Russ. J. Org. Chem. 2008; 44: 1215
34 The appropriate 4-(trifluoromethyl)-7,8-dihydroquinolin-5(6H)-one (1 equiv) was dissolved in EtOH. To this solution, hydroxylamine hydrochloride (10 equiv) and pyridine (10 equiv) were added and refluxed for 4 h.Compound 5a: ¹H NMR (400 MHz, CDCl₃): δ = 1.89 (2 H, tt, J = 6.5Hz, 6.5Hz, CH₂CH ₂CH₂), 2.62 (3 H, s, CH₃), 2.88 (2 H, t, J = 6.5Hz, CH ₂C_qNO), 2.93 (2 H, t, J = 6.5Hz, CH ₂C_qN), 7.36 (1 H, s, CH), 8.45 (1H, br. s, OH). ¹³C NMR (100 MHz, CDCl₃): δ = 20.2, 23.8, 24.3, 33.3, 119.6, 122.9, 122.9, 135.8, 152.4, 158.2, 162.2. ¹⁹F NMR (376.5 MHz, CDCl₃): δ = –60.05.
35 Yoshida Y, Shimonishi K, Sakakura Y, Okada S, Aso N. Synthesis 1999; 1633
36 The appropriate 4-(trifluoromethyl)-7,8-dihydroquinolin-5(6H)-one oxime (1 equiv) was dissolved in MeCN. To this solution, p-toluenesulfonyl chloride (1.5 equiv), Et₃N (1.5 equiv) and N,N,N′,N′-tetramethyl-1,3-propanediamine (0.1 equiv) were added and stirred overnight at r.t.Compound 6a: ¹H NMR (400 MHz, CDCl₃): δ = 1.88 (2H, tt, J = 6.5Hz, J = 6.5Hz, CH₂CH ₂CH₂), 2.44 (3H, s, CH ₃C_qCHCH), 2.61 (3 H, s, CH ₃C_qN), 2.92 (2 H, t, J = 6.5Hz, CH₂CNO), 2.96 (2 H, t, J = 6.5Hz, CH₂CH₂CH ₂C_qN), 7.33 (2 H, d, J = 7.7Hz, 2 × CH₃C_qCH); 7.34 (1 H, s, CF₃C_qCH), 7.88 (2 H, d, J = 7.7Hz, 2 × CH₃C_qCHCH). ¹³C NMR (100 MHz, CDCl₃): δ = 19.7, 21.8, 24.6, 26.0, 33.5, 119.1, 119.5, 122.3, 129.2, 129.7, 132.3, 136.3, 145.2, 160.4, 160.9, 162.9. ¹⁹F NMR (376.5 MHz, CDCl₃): δ = –60.2.
37 Jössang-Yanagida A, Gansser C. J. Heterocycl. Chem. 1978; 15: 249
38 The appropriate O-tosyl-4-(trifluoromethyl)-7,8-dihydroquinolin-5(6H)-one oxime (1 equiv) was dissolved in an EtOH–H₂O mixture (6:4). KOAc (2.1–8.4 equiv) was added, and the mixture was refluxed until full conversion (1–8 d).Compound 7a: ¹H NMR (400 MHz, CDCl₃): δ = 2.32–2.42 (4 H, m, COCH ₂CH ₂), 2.62 (3 H, s, CH₃), 3.08–3.14 (2 H, m, CH₂C_qN), 7.32 (1 H, s, CH), 7.99 (1 H, br. s, NH). ¹³C NMR (100 MHz, CDCl₃): δ = 24.0, 27.2, 32.3, 33.0, 117.8, 122.4, 128.2, 129.7, 156.1, 157.0, 174.0. ¹⁹F NMR (376.5 MHz, CDCl₃): δ = –63.2.Compound 8a: ¹H NMR (400 MHz, CDCl₃): δ = 1.38 (3 H, t, J = 7.1 Hz, CH ₃CH₂), 2.24–2.41 (4 H, m, COCH ₂CH ₂), 2.55 (3 H, s, CH₃), 2.84 (2 H, t, J = 7.1 Hz, CH₂C_qN), 4.35 (2 H, q, J = 7.1 Hz, CH₃CH ₂), 7.25 (1 H, s, CH). ¹³C NMR (100MHz, CDCl₃): δ = 14.0, 22.8, 29.0, 30.5, 33.1, 62.4, 117.9, 122.9, 129.8, 138.3, 152.2, 153.8, 168.1. ¹⁹F NMR (376.5 MHz, CDCl₃): δ = –63.2.
39 Opanasenko M, Shamzhy M, Lamač M, Čejka J. Catal. Today 2013; 204: 94
40 Clarysse S, Brouwers J, Tack J, Annaert P, Augustijns P. Eur. J. Pharm. Sci. 2011; 43: 260
41 Wuyts B, Brouwers J, Mols R, Tack J, Annaert P, Augustijns P. J. Pharm. Sci. 2013; 102: 3800
42 Augustijns P, Wuyts B, Hens B, Annaert P, Butler J, Brouwers J. Eur. J. Pharm. 2014; 57: 322
43 Brouwers J, Tack J, Augustijns P. Int. J. Pharm. 2007; 336: 302
44 Matsson P, Pedersen JM, Norinder U, Bergström CA. S, Artursson P. Pharm. Res. 2009; 26: 1816
45 Holmstock N, Annaert P, Augustijns P. Drug Metab. Dispos. 2012; 40: 1473
46 Obach RS. Drug Metab. Dispos. 1999; 27: 1350

Supplementary Material

Supporting Information (PDF)